Abstract
The pathogenesis of non-alcoholic fatty liver disease (NAFLD) is not entirely understood. Recently, the role of microRNA in this liver disease entity and its implication in disease pathogenesis and therapeutic potential has advanced rapidly over the year. While the regulation of miRNA function and its mechanism of actions on translational control of target mRNA expression remain unknown, advances in miRNA research allow identification and biochemical characterization of events that limit protein expression, which is crucial in various forms of human diseases and their subsequent development. It is hoped that further understanding of the role of microRNA in NAFLD will advance potential therapeutics and preventive measures to modify and alter this disease process.
Keywords: microRNA, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome
Current Pharmaceutical Design
Title: Role of microRNAs in Non-Alcoholic Steatohepatitis
Volume: 16 Issue: 17
Author(s): Onpan Cheung and Arun J. Sanyal
Affiliation:
Keywords: microRNA, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome
Abstract: The pathogenesis of non-alcoholic fatty liver disease (NAFLD) is not entirely understood. Recently, the role of microRNA in this liver disease entity and its implication in disease pathogenesis and therapeutic potential has advanced rapidly over the year. While the regulation of miRNA function and its mechanism of actions on translational control of target mRNA expression remain unknown, advances in miRNA research allow identification and biochemical characterization of events that limit protein expression, which is crucial in various forms of human diseases and their subsequent development. It is hoped that further understanding of the role of microRNA in NAFLD will advance potential therapeutics and preventive measures to modify and alter this disease process.
Export Options
About this article
Cite this article as:
Cheung Onpan and J. Sanyal Arun, Role of microRNAs in Non-Alcoholic Steatohepatitis, Current Pharmaceutical Design 2010; 16 (17) . https://dx.doi.org/10.2174/138161210791208866
DOI https://dx.doi.org/10.2174/138161210791208866 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Psychosocial Factors and Central Sensitivity Syndromes
Current Rheumatology Reviews Current Treatment Strategies for Multiple Sclerosis - Efficacy Versus Neurological Adverse Effects
Current Pharmaceutical Design Targeting the Platelet Integrin GPIIb/IIIa
Current Pharmaceutical Design Novel Epigenetic Targets in Lymphoproliferative Disorders
Current Cancer Drug Targets An Overview of Galenic Preparation Methods for Medicinal Cannabis
Current Bioactive Compounds Synthesis and Screening of N-Alkyl Hydroxamates for Inhibition of Cancer Cell Proliferation
Combinatorial Chemistry & High Throughput Screening Targeting Bcl-2 in CLL
Current Medicinal Chemistry Endothelium and Oxidative Stress: The Pandora's Box of Cerebral (and Non-Only) Small Vessel Disease?
Current Molecular Medicine The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments
Current Pediatric Reviews Toward The Rational Design of Cell Fate Modifiers Notch Signaling as a Target for Novel Biopharmaceuticals
Current Pharmaceutical Biotechnology Dysregulation of RNA Mediated Gene Expression in Motor Neuron Diseases
CNS & Neurological Disorders - Drug Targets Growth Velocity, Final Height and Bone Mineral Metabolism of Short Children Treated Long Term with Growth Hormone
Current Pharmaceutical Biotechnology Experience with Androgen Deprivation Therapy for Prostate Cancer in Japan and Future Perspectives
Current Cancer Drug Targets Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Are We There Yet? The Clinical Potential of Intranasal Oxytocin in Psychiatry
Current Psychiatry Reviews Inhibition of Platelet Glycoprotein Ib and Its Antithrombotic Potential
Current Pharmaceutical Design Assessment of Acute Coronary Syndromes: Focus on Novel Biomarkers
Current Medicinal Chemistry Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Recent Approaches in Chemoprevention of Prostate Cancer
Current Cancer Drug Targets The Glutamatergic Hypothesis for Down Syndrome: The Potential Use of N-Methyl-D-Aspartate Receptor Antagonists to Enhance Cognition and Decelerate Neurodegeneration
CNS & Neurological Disorders - Drug Targets